ClinicalTrials.gg
Status unknownNCT00864877Updated Mar 19, 2009

Comparison of Biodegradable & Metal Plates for Fixing Ankle Fracture

An interventional study of biodegradable fixation system (Inion OTPS FreedomPlateTM) in Distal Fibular Fracture, Bimalleolar Fracture and Trimalleolar Fracture, sponsored by Inion Oy. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2009-03-19.

Sponsored by Inion Oy · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2009), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
18 Years to 60 Years
Sex
All
01

Study summary

A randomised, prospective clinical investigation to compare post-operative fracture healing and complication rate after the fixation of ankle fractures using the Inion OTPS FreedomPlateTM Biodegradable Fixation System versus conventional stainless steel metal screws and plates.

The objectives of the investigation are

  • to compare post-operative fracture healing (union rates, time-to-union), and the complication rates (hardware failure, infection) between the two Plating Systems (biodegradable INION OTPS FreedomPlateTM vs. Stainless Steel 3.5 Reconstruction or DCP plate, or 1/3 Semitubular plates) at the clinical setting of Ankle fractures
  • to study the safety of the clinical application of the biodegradable plating system of Inion OTPS FreedomPlateTM at the acute Ankle fracture setting.
02

Conditions studied

  • Distal Fibular Fracture
  • Bimalleolar Fracture
  • Trimalleolar Fracture

Browse trials for

Keywords

  • retrospective
  • comparison
  • biodegradable
  • implant
  • ankle fracture
03

In context

Ankle Fractures

203 studies on the registry are indexed under Ankle Fractures; 45 are open to participants now.

Browse Ankle Fractures studies →

Lead sponsor

Inion Oy is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is willing and able to understand, sign and date the study-specific, Institutional Review Board/Ethics Committee approved patient and applicable privacy regulations.
  2. Patient must require surgical treatment of a ankle fracture, with a distal fibular (i.e., lateral malleolus) fracture (isolated, closed, unilateral, non-comminuted) including either instable/dislocated Weber class B or any Weber class C fracture that cannot be anatomically reconstructed accurately without open procedure, or bimalleolar fracture with lateral malleolus fracture (as described above) and medial malleolus fracture (closed, unilateral, non-comminuted), or trimalleolar fracture with lateral and medial malleolus fractures as described above and posterior malleolus fracture with less than ¼ of the articular surface fractured
  3. Fresh/acute fractures (seen within seventy-two hours of the injury)
  4. Aged between 18 to 60 years
  5. Skeletally mature
  6. Willingness to accept randomisation either to the test or control group
  7. Willingness and ability to comply with all investigation procedures pre- and post-operation.

Exclusion criteria

Exclusion Criteria:

  1. of operative internal plate fixations
  2. Contraindications for the Inion OTPS FreedomPlateTM Biodegradable Fixation System:

    • active or potential infection
    • patient's conditions, including limited blood supply, insufficient quantity or quality of bone, and where patient cooperation cannot be guaranteed (e.g., alcoholism, drug abuse)
    • high-load bearing applications
  3. Multiple trauma, head injury, bilateral lower extremity fractures, upper extremity fractures
  4. Any concomitant painful or disabling disease of the lower limb that would interfere with evaluation of the affected ankle
  5. Previous ankle fracture
  6. Patients who most likely will not learn to walk with crutches (e.g., due to being severely overweight)
  7. Bone
  8. Osteomyelitis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment

Interventions

  • Devicebiodegradable fixation system (Inion OTPS FreedomPlateTM)

    Also known as: Inion OTPS(tm) FreedomPlate

06

What researchers measure

Primary outcomes

  1. The functional performance will be primarily determined by the Olerud and Molander Ankle Score

    Time frame: at 2, 6 and 12 weeks, and 12 and 24 months post-operatively

07

Study locations

1 site
  • Leeds General Infirmary
    Leeds, LS13EX, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009 and a primary completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2009
First posted
Mar 19, 2009
Start
May 2009
Primary completionEst.
Apr 2012
Last update
Mar 19, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00864877
Lead sponsor
Inion Oy
First posted
Mar 19, 2009
Start date
May 2009
Primary completion
Apr 2012 (estimated)
Last update
Mar 19, 2009

Study contacts

Peter Giannoudis, Professor
principal investigator · Leeds General Infirmary

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion